Brands International, a Canadian drug manufacturer, limited an FDA inspection and had manufacturing quality violations including mold contamination.
What happened
FDA inspected the drug manufacturing facility in Newmarket, Ontario, Canada, from June 17 to 21, 2024. Investigators found that management limited and delayed the inspection and cited CGMP violations—current good manufacturing practice, FDA's manufacturing quality rules—including inadequate mold complaint investigation, release without active ingredient testing, untested incoming components including glycerin, poor storage and pest control, and weak quality unit oversight. The firm recalled Kissable Oatmeal Daily Moisturizing Body Lotion for mold and later expanded the recall, but FDA says it did not answer requests for more information.
What FDA found
FDA says the firm limited and delayed the inspection, including hostile behavior and withheld or delayed records.
section 501(j) of the FD&C Act, 21 U.S.C. 351(j)FDA says the firm did not thoroughly investigate a customer complaint of mold in lotion or determine whether other products using the same pumps were affected.
21 CFR 211.192FDA says the firm released drug batches without testing the identity and strength of active ingredients and used test methods that were not validated.
21 CFR 211.165(a)FDA says the firm did not test incoming components and active ingredients for identity and relied on supplier certificates without proving their reliability, and did not test glycerin for DEG or EG.
21 CFR 211.84(d)(1) and 211.84(d)(2)FDA says the facility stored materials in uncontrolled trailers and outdoors and had filthy pest traps with an ongoing pest problem.
21 CFR 211.42(b)FDA says the quality unit did not adequately oversee manufacturing, with no process validation, cleaning validation, or ongoing stability program.
21 CFR 211.22; 211.100(a); 211.67(b); 211.137
What FDA wants
FDA asks the firm to provide comprehensive remediation plans, independent assessments, retain-sample testing results, and risk assessments for U.S. products, including DEG/EG test results within 30 calendar days. FDA also recommends a qualified CGMP consultant and says the firm must respond to requests about the expanded recall.
Who should pay attention
- brands that buy finished drugs or lotions from this contract manufacturer
- companies using glycerin or other high-risk components
- quality teams managing supplier qualification and complaint investigations
This is a summary. Read the original letter on fda.gov.